- Home
- NSTS vs MURA Comparison
NSTS vs MURA Comparison
Compare NSTS & MURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSTS
- MURA
- Stock Information
- Founded
- NSTS 1921
- MURA 2013
- Country
- NSTS United States
- MURA Ireland
- Employees
- NSTS N/A
- MURA N/A
- Industry
- NSTS Savings Institutions
- MURA
- Sector
- NSTS Finance
- MURA
- Exchange
- NSTS Nasdaq
- MURA Nasdaq
- Market Cap
- NSTS 59.1M
- MURA 62.2M
- IPO Year
- NSTS N/A
- MURA N/A
- Fundamental
- Price
- NSTS $11.19
- MURA $3.45
- Analyst Decision
- NSTS
- MURA Strong Buy
- Analyst Count
- NSTS 0
- MURA 4
- Target Price
- NSTS N/A
- MURA $16.00
- AVG Volume (30 Days)
- NSTS 7.0K
- MURA 56.9K
- Earning Date
- NSTS 11-13-2024
- MURA 11-13-2024
- Dividend Yield
- NSTS N/A
- MURA N/A
- EPS Growth
- NSTS N/A
- MURA N/A
- EPS
- NSTS N/A
- MURA N/A
- Revenue
- NSTS $6,187,000.00
- MURA N/A
- Revenue This Year
- NSTS N/A
- MURA N/A
- Revenue Next Year
- NSTS N/A
- MURA N/A
- P/E Ratio
- NSTS N/A
- MURA N/A
- Revenue Growth
- NSTS N/A
- MURA N/A
- 52 Week Low
- NSTS $8.57
- MURA $2.88
- 52 Week High
- NSTS $11.50
- MURA $6.25
- Technical
- Relative Strength Index (RSI)
- NSTS 60.08
- MURA 48.79
- Support Level
- NSTS $11.08
- MURA $3.31
- Resistance Level
- NSTS $11.13
- MURA $3.66
- Average True Range (ATR)
- NSTS 0.13
- MURA 0.18
- MACD
- NSTS -0.02
- MURA -0.01
- Stochastic Oscillator
- NSTS 71.05
- MURA 45.45
About NSTS NSTS Bancorp Inc.
NSTS Bancorp Inc is a savings and loan holding company regulated Federal Reserve Board. The company was formed to serve as the North Shore Trust and Savings stock holding company. The Bank is a wholly-owned subsidiary of the company and operates as a traditional savings institution focused on serving the banking needs of customers in our market area of Lake County, Illinois and adjacent communities.
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.